The series capstone maps the full clinical landscape. The hosts review primary and secondary indications — opioid use disorder (the flagship), other substance use disorders (cocaine, alcohol, methamphetamine, nicotine), PTSD, TBI, and depression — with mechanistic rationale for each. An honest read of the evidence base is provided: decades of observational and offshore-clinic data exist, but randomized controlled trials are scarce. The landmark Stanford MISTIC magnesium-ibogaine study in special-operations veterans is analyzed for design, findings, and caveats. Current and future programs are detailed — DemeRx/atai (DMX-1002) for OUD, continued Stanford work, the Texas UTHealth-UTMB consortium (SB 2308), Oregon admitteds supervised-access law, and federal interest — all grounded to sourced information. Regulatory and manufacturing realities (Sche ...